Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 126997091 | 12699709 | 1 | I | 20160815 | 20160830 | 20160830 | EXP | CA-NORTH CREEK PHARMACEUTICALS LLC-2016VTS00061 | NORTH CREEK PHARMACEUTICALS | GHANNOUM M, CORMIER M, BERNIER-JEAN A, BRINDAMOUR D, DEZIEL C, BOUCHARD J. EXTRACORPOREAL TREATMENTS IN A DAPSONE OVERDOSE: A CASE REPORT. CLIN TOXICOL (DOI: 10.1080/15563650.2016.1209769). 2016 | 23.00 | YR | F | Y | 63.00000 | KG | 20160830 | OT | CA | CA |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 126997091 | 12699709 | 1 | PS | DAPSONE. | DAPSONE | 1 | Oral | 2.2 G, UNK | 204074 | 2.2 | G |
Indications of drugs used
| no results found |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 126997091 | 12699709 | HO |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 126997091 | 12699709 | Cyanosis central | |
| 126997091 | 12699709 | Haemodialysis | |
| 126997091 | 12699709 | Haemodynamic instability | |
| 126997091 | 12699709 | Headache | |
| 126997091 | 12699709 | Mental status changes | |
| 126997091 | 12699709 | Methaemoglobinaemia | |
| 126997091 | 12699709 | Overdose | |
| 126997091 | 12699709 | Thrombocytopenia | |
| 126997091 | 12699709 | Toxicity to various agents |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| no results found |